Mesa Laboratories, Inc. (MLAB) SEC Filings & Earnings Calls

Execution risk in achieving expected cost savings and reinvestment benefits

“Actual charges and cash expenditures associated with the Restructuring Program may differ from these estimates” · word for word

Revenue decline from Clinical Genomics refocusing may be larger than expected

“Revenue will be lower as a result” · word for word

International employee consultation processes may delay completion

“Estimates of the headcount reductions, timing and charges related to certain international operations remain subject to the completion of applicable local employee consultation processes” · word for word

SDC division facing fulfillment and delivery execution challenges impacting revenue timing.

“SDC organic decline 3.6% primarily attributable to fulfillment and delivery execution challenges that negatively impacted the timing of customer shipments.”

China market weakness continues to pressure CG division revenue.

“While revenue in China continued to decrease, the year-over-year reduction was significantly smaller than in the prior year period.” · word for word

Valuation Allowance on Deferred Tax Assets

“Given our current earnings and anticipated future earnings, we believe that there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to allow us to reach a conclusion that a significant portion of the valuation allowance will no longer be needed.” · word for word

Debt Covenant Compliance

“As of June 30, 2026 , we were in compliance with all covenants under the Credit Facility.” · word for word

Interest Rate Risk

“Borrowings under our Credit Facility bear interest at a Secured Overnight Financing Rate ("SOFR") rate or a base rate, plus an applicable spread that varies with our total net leverage ratio.” · word for word

CEO transition risk

“After serving as President and Chief Executive Officer since 2017, Gary Owens stepped down from his role in April 2026.” · word for word

Biopharmaceutical Development segment weakness

“These results were partially offset by profitability declines in the Biopharmaceutical Development segment.” · word for word

Macroeconomic and regulatory headwinds

“In fiscal year 2026, Mesa operated in a dynamic environment characterized by regulatory and policy shifts as well as ongoing macroeconomic challenges.” · word for word

No material risk; internal promotion indicates stability.

“internal promotion; no disagreements”

Tariff cost pressure and demand impact

“These tariffs increase the costs of imported supplies and components, which has required us to implement surcharges and/or increase the prices of certain of our finished goods, which can adversely impact demand for our products and our competitive positioning, resulting in lower revenues.” · word for word

China localization policies reducing demand

“For example, the Chinese government has issued a series of policies in the past several years to promote the development and use of local medical devices. These types of policies may reduce demand for our products and adversely affect our financial results.” · word for word

CEO transition execution risk

“In March 2026, we announced a transition in our Chief Executive Officer ("CEO") position, effective in April 2026. Leadership transitions, including changes in executive management, can be disruptive and may result in uncertainty among employees, customers and other business partners.” · word for word

Dialyguard product line obsolescence

“Ongoing technological advancements, including the development of dialysis machines with integrated dialysis calibration capabilities and shifts toward home-based treatments, have and may continue to adversely affect demand for our renal care products.” · word for word

Export controls continue to disrupt BPD shipments, causing significant revenue decline.

“Shipping delays associated with export controls prevented shipment of several Peptide systems during the quarter.”

BPD commercial execution challenges may persist, impacting growth.

“Challenges associated with commercial execution during the quarter.” · word for word

CEO departure may disrupt strategic initiatives and investor confidence.

“Departure of Gary Owens as President and Chief Executive Officer, effective on or about April 13, 2026.” · word for word

Leadership transition risk; new CEO may implement strategic changes.

“Appointment of new CEO with start date between April 1-13, 2026.”

China regulatory and tariff headwinds causing CG China revenue contraction of 57% YoY; step function decline since Q1.

“A contraction in China revenues of approximately $1.2 million, or 57% versus the same quarter prior year... China regulatory and tariff headwinds resulted in a step function contraction beginning 1Q26” · word for word

FX headwinds impacting gross profit by 120bps; tariff impacts negligible but monitored.

“headwinds of 120 bps from FX and a negligible impact from tariffs” · word for word

Clinical Genomics revenue decline

“Clinical Genomics total revenues $11,767 vs $12,667 for three months ended December 31, 2025 and 2024, respectively.”

Leverage and debt service

“Total debt (Term Loan + Revolver) ~$166.7M; net leverage ratio covenant max 4.0x; interest expense remains significant.”

China revenue decline

“China revenue decreased 28% year-over-year in Q3 2025.”

Clinical Genomics hardware decline

“Clinical Genomics hardware and software revenue declined 54% year-over-year in Q3 2025.”

Leverage risk

“Total net leverage ratio covenant of 4.0x; revolver drawn $106M.”

Tariff and FX headwinds impacting margins

“Quarterly performance was impacted by headwinds of 40 bps from tariffs and 60 bps from FX.” · word for word

CG China revenue decline due to macroeconomic headwinds

“A contraction in China revenues of approximately $1.7M, or 58% versus the same quarter prior year.” · word for word